Ann Dermatol.  2017 Feb;29(1):55-60. 10.5021/ad.2017.29.1.55.

The Advantage of Cyclosporine A and Methotrexate Rotational Therapy in Long-Term Systemic Treatment for Chronic Plaque Psoriasis in a Real World Practice

• Choi CW
• Kim BR
• Ohn J
• Youn SW

• KMID: 2368028
• DOI: http://doi.org/10.5021/ad.2017.29.1.55

Abstract

BACKGROUND
Psoriasis is a chronic inflammatory disease. In the treatment of psoriasis, cyclosporine is commonly prescribed systemic agents. However, long-term use of cyclosporine is not recommended because of side effects such as nephrotoxicity or hypertension.
OBJECTIVE
To ascertain the improved safety of rotational therapy using cyclosporine and methotrexate, we investigated the frequency of abnormal results in laboratory test after long term rotational therapy using cyclosporine and methotrexate.
METHODS
From January 2009 to June 2014, patients who were treated with cyclosporine or methotrexate were enrolled. The clinical data and usage of medications were reviewed. Laboratory tests were conducted before starting the treatment and regularly follow-up. The occurrences of any laboratory abnormalities during the treatments were investigated.
RESULTS
A total of 21 psoriatic patients were enrolled. The mean of medication period and cumulative dose of cyclosporine and methotrexate were 497.81±512.06 days and 115.68±184.34 g in cyclosporine and 264.19±264.71 days and 448.71±448.63 mg in methotrexate. Laboratory abnormalities were found in total two patients after rotational therapy: two patients (9.5%) in aspartate aminotransferase/alanine aminotransferase and one patient (4.8%) in uric acid. No laboratory abnormalities were found in renal function test.
CONCLUSION
We found that the rotational approaches using cyclosporine and methotrexate reduced the possibility of the development of nephrotoxicity. In addition to other advantage such as quick switching from one agent to another, the rotational therapy using cyclosporine and methotrexate can minimize the adverse events during the systemic treatment of chronic plaque psoriasis.

Keyword

Clinical chemistry tests; Combined modality therapy; Cyclosporine; Methotrexate; Psoriasis

MeSH Terms

Aspartic Acid
Clinical Chemistry Tests
Combined Modality Therapy
Cyclosporine*
Follow-Up Studies
Humans
Hypertension
Methotrexate*
Psoriasis*
Uric Acid
Aspartic Acid
Cyclosporine
Methotrexate
Uric Acid

Reference

1. Greaves MW, Weinstein GD. Treatment of psoriasis. N Engl J Med. 1995; 332:581–588.

2. Raho G, Koleva DM, Garattini L, Naldi L. The burden of moderate to severe psoriasis: an overview. Pharmacoeconomics. 2012; 30:1005–1013.

3. Youn SW, Kim BR, Lee JH, Song HJ, Choe YB, Choi JH, et al. Comparison of treatment goals for moderate-to-severe psoriasis between Korean dermatologists and the european consensus report. Ann Dermatol. 2015; 27:184–189.

4. Colombo MD, Cassano N, Bellia G, Vena GA. Cyclosporine regimens in plaque psoriasis: an overview with special emphasis on dose, duration, and old and new treatment approaches. ScientificWorldJournal. 2013; 2013:805705. DOI: 10.1155/2013/805705.

5. Rosmarin DM, Lebwohl M, Elewski BE, Gottlieb AB. National Psoriasis Foundation. Cyclosporine and psoriasis: 2008 National Psoriasis Foundation Consensus Conference. J Am Acad Dermatol. 2010; 62:838–853.

6. Lebwohl M, Menter A, Koo J, Feldman SR. Combination therapy to treat moderate to severe psoriasis. J Am Acad Dermatol. 2004; 50:416–430.

7. Weinstein GD, White GM. An approach to the treatment of moderate to severe psoriasis with rotational therapy. J Am Acad Dermatol. 1993; 28:454–459.

8. Menter MA, See JA, Amend WJ, Ellis CN, Krueger GG, Lebwohl M, et al. Proceedings of the Psoriasis Combination and Rotation Therapy Conference. Deer Valley, Utah, Oct. 7-9, 1994. J Am Acad Dermatol. 1996; 34:315–321.

9. Koo J, Liao W. Update on psoriasis therapy: a perspective from the USA. Keio J Med. 2000; 49:20–25.

10. Ellis CN, Fradin MS, Messana JM, Brown MD, Siegel MT, Hartley AH, et al. Cyclosporine for plaque-type psoriasis. Results of a multidose, double-blind trial. N Engl J Med. 1991; 324:277–284.

11. Berth-Jones J, Henderson CA, Munro CS, Rogers S, Chalmers RJ, Boffa MJ, et al. Treatment of psoriasis with intermittent short course cyclosporin (Neoral). A multicentre study. Br J Dermatol. 1997; 136:527–530.

12. Ho VC, Griffiths CE, Berth-Jones J, Papp KA, Vanaclocha F, Dauden E, et al. Intermittent short courses of cyclosporine microemulsion for the long-term management of psoriasis: a 2-year cohort study. J Am Acad Dermatol. 2001; 44:643–651.

13. Radmanesh M, Rafiei B, Moosavi ZB, Sina N. Weekly vs. daily administration of oral methotrexate (MTX) for generalized plaque psoriasis: a randomized controlled clinical trial. Int J Dermatol. 2011; 50:1291–1293.

14. Kumar B, Saraswat A, Kaur I. Short-term methotrexate therapy in psoriasis: a study of 197 patients. Int J Dermatol. 2002; 41:444–448.

15. García-Bustínduy M, Escoda M, Guimerá FJ, Sáez M, Dorta S, Fagundo E, et al. Safety of long-term treatment with cyclosporin A in resistant chronic plaque psoriasis: a retrospective case series. J Eur Acad Dermatol Venereol. 2004; 18:169–172.

16. Ho VC, Griffiths CE, Albrecht G, Vanaclocha F, León-Dorantes G, Atakan N, et al. Intermittent short courses of cyclosporin (Neoral(R)) for psoriasis unresponsive to topical therapy: a 1-year multicentre, randomized study. Br J Dermatol. 1999; 141:283–291.

17. Tostivint I, du Montcel ST, Jaudon MC, Mallet A, Le Hoang P, Bodaghi B, et al. Renal outcome after ciclosporin-induced nephrotoxicity. Nephrol Dial Transplant. 2007; 22:880–885.

18. Okubo Y, Natsume S, Usui K, Amaya M, Tsuboi R. Low-dose, short-term ciclosporin (Neoral®) therapy is effective in improving patients' quality of life as assessed by Skindex-16 and GHQ-28 in mild to severe psoriasis patients. J Dermatol. 2011; 38:465–472.